ProQinase Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 62

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

  • Investments
  • 1

ProQinase General Information

Description

Provider of contract research and drug discovery services in Germany. The company's offerings include recombinant target proteins, biochemical and cell-based assays, vivo tumor models in mice, protein kinases and preclinical testing services, enabling clients with cancer drug discovery projects to get custom-tailored services.

Contact Information

Formerly Known As
BIOMEC Technologie Transfer GmbH
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Breisacher Street 117
  • 79106 Freiburg
  • Germany
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Breisacher Street 117
  • 79106 Freiburg
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProQinase Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ProQinase‘s full profile, request access.

Request a free trial

ProQinase Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of contract research and drug discovery services in Germany. The company's offerings include recombinant target
Drug Discovery
Freiburg, Germany
62 As of 2022

Abingdon, United Kingdom
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ProQinase Competitors (41)

One of ProQinase’s 41 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
BPS Bioscience Corporation San Diego, CA
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
etherna Formerly VC-backed Niel, Belgium
TME Pharma Formerly VC-backed Berlin, Germany
You’re viewing 5 of 41 competitors. Get the full list »

ProQinase Patents

ProQinase Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220073921-A1 Aptamer and use of the aptamer in the diagnosis and treatment of cancer Inactive 21-Jan-2019
EP-3583845-A1 Mammary fat pad (mfp) tumor cell inoculation to avoid tumor ulceration Inactive 19-Jun-2018
EP-2922857-A1 Thioether derivatives as protein kinase inhibitors Active 20-Nov-2012
EP-2922857-B1 Thioether derivatives as protein kinase inhibitors Inactive 20-Nov-2012
US-20150328219-A1 Thioether derivatives as protein kinase inhibitors Active 20-Nov-2012 A61K31/52
To view ProQinase’s complete patent history, request access »

ProQinase Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProQinase Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ProQinase‘s full profile, request access.

Request a free trial

ProQinase Investments (1)

ProQinase’s most recent deal was a Joint Venture with Novithera. The deal was made on 24-Oct-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Novithera 24-Oct-2016 Joint Venture Therapeutic Devices
To view ProQinase’s complete investments history, request access »

ProQinase Exits (1)

ProQinase’s most recent exit was on 24-Oct-2016 from Novithera. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Novithera 24-Oct-2016 Completed
  • 2 buyers
To view ProQinase’s complete exits history, request access »

ProQinase Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Bioassay Labor für biologische Analytik Heidelberg, Germany 2002

ProQinase FAQs

  • When was ProQinase founded?

    ProQinase was founded in 2001.

  • Where is ProQinase headquartered?

    ProQinase is headquartered in Freiburg, Germany.

  • What is the size of ProQinase?

    ProQinase has 62 total employees.

  • What industry is ProQinase in?

    ProQinase’s primary industry is Drug Discovery.

  • Is ProQinase a private or public company?

    ProQinase is a Private company.

  • What is ProQinase’s current revenue?

    The current revenue for ProQinase is .

  • Who are ProQinase’s investors?

    ChinaEquity Group and KTB Klinik für Tumorbiologie have invested in ProQinase.

  • Who are ProQinase’s competitors?

    Adaptimmune Therapeutics, BPS Bioscience, Sygnature Discovery, etherna, and TME Pharma are some of the 41 competitors of ProQinase.

  • When was ProQinase acquired?

    ProQinase was acquired on 04-Feb-2019.

  • Who acquired ProQinase?

    ProQinase was acquired by Reaction Biology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process